Search hospitals > Illinois > Kewanee
Illinois CancerCare-Kewanee Clinic
Claim this profileKewanee, Illinois 61443
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
376 reported clinical trials
2 medical researchers
Summary
Illinois CancerCare-Kewanee Clinic is a medical facility located in Kewanee, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Kewanee Clinic is involved with conducting 376 clinical trials across 471 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage I
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Bryan A. FallerCrossroads Cancer Center6 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
239 reported clinical trials
297 drugs studied
James L. WadeDecatur Memorial Hospital4 years of reported clinical research
Studies Breast Cancer
Studies Bladder Cancer
11 reported clinical trials
20 drugs studied
Clinical Trials running at Illinois CancerCare-Kewanee Clinic
Lung Cancer
Prostate Cancer
Breast Cancer
Pancreatic Cancer
Cancer
Bladder Cancer
Breast cancer
Ovarian Cancer
Kidney Cancer
Esophageal cancer
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting2 awards Phase 310 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Illinois CancerCare-Kewanee Clinic?
Illinois CancerCare-Kewanee Clinic is a medical facility located in Kewanee, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Kewanee Clinic is involved with conducting 376 clinical trials across 471 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Where is Illinois CancerCare-Kewanee Clinic located?
**Illinois CancerCare-Kewanee Clinic**
- **Address:** 1051 W South St, Kewanee, IL 61443
- **Location:** Approximately 1 mile west of downtown Kewanee, near the intersection of West South Street and Tenney Street.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Illinois CancerCare-Kewanee Clinic, please call (309) 243-3500 or toll-free at (866) 662-6564.
What insurance does Illinois CancerCare-Kewanee Clinic accept?
The Illinois CancerCare-Kewanee Clinic accepts most prescription insurance plans, including Medicare and Medicaid, and offers delivery options for prescriptions. They have a dedicated team focused on making medication affordable for patients. The clinic is affiliated with OSF Saint Luke's Medical Center, which accepts a variety of commercial and government health insurance plans. Patients should verify their insurance coverage and bring their insurance identification cards on their first visit.
What awards or recognition has Illinois CancerCare-Kewanee Clinic received?
Illinois CancerCare-Kewanee Clinic, situated in Kewanee, Illinois, specializes in treating cancer and blood diseases as part of the larger Illinois CancerCare practice. It is distinguished by its dedication to clinical research, maintaining around 100 open clinical cancer research trials at any given time. The clinic has earned recognition from the Quality Oncology Practice Initiative (QOPI®) Certification Program for meeting the highest national standards for quality cancer care and is a proud member of Heartland NCORP, leading the nation in cancer research enrollment.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.